Zynex (NASDAQ:ZYXI) Releases Q1 2025 Earnings Guidance

Zynex (NASDAQ:ZYXI) issued an update on its first quarter 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of -0.300- for the period, compared to the consensus earnings per share estimate of 0.060. The company issued revenue guidance of $30.0 million-, compared to the consensus revenue estimate of $53.5 million.

Zynex Trading Down 2.4 %

ZYXI stock traded down $0.17 during midday trading on Tuesday, hitting $7.00. The stock had a trading volume of 119,612 shares, compared to its average volume of 111,921. The firm has a market cap of $222.92 million, a P/E ratio of 46.67 and a beta of 0.81. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66. Zynex has a 1-year low of $5.44 and a 1-year high of $13.19. The business has a fifty day moving average price of $7.74 and a two-hundred day moving average price of $8.02.

Zynex (NASDAQ:ZYXI) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.11). Zynex had a net margin of 2.49% and a return on equity of 13.05%. During the same quarter in the prior year, the company earned $0.04 earnings per share. On average, sell-side analysts predict that Zynex will post 0.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Zynex in a research report on Friday, December 6th.

Insiders Place Their Bets

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $7.68, for a total value of $76,800.00. Following the transaction, the chief financial officer now directly owns 19,738 shares in the company, valued at $151,587.84. The trade was a 33.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 30,000 shares of company stock valued at $227,100. Corporate insiders own 52.13% of the company’s stock.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.